In general, METTL14 is an independent predictor of beneficial prognosis in p53‐WT CRC patients and functions as a tumor suppressor by selectively maturating miR‐6769b‐3p and miR‐499a‐3p, and then inhibiting the expression of SLC2A3 and PGAM1, and rewiring the cellular metabolism to reduce glycolysis and repress p53‐WT CRC tumorigenesis (Fig 6I). The gene discussed is SLC2A3; the disease is neoplasm.